Characteristics and Mechanism of Denosumab-treated Giant Cell Tumor of Bone
Status:
Unknown status
Trial end date:
2019-05-01
Target enrollment:
Participant gender:
Summary
Giant cell tumor of bone (GCTb) is a primary, osteolytic, benign tumor of the bone. Surgery
is the commonly used treatment. Discovery of RANKL and its human monoclonal antibody,
denosumab, led to use of denosumab for treatment of GCT. The aim of this study was to
evaluate clinical and pathological results of treatment of relapsed or refractoriness GCT
with denosumab and to assess adverse effect profile and recurrence rate.